2月10日 - ** Hoth Therapeutics HOTH.O股价盘前上涨3.9%至0.89美元
** 公司称其肥胖症实验药物HT-VA GDNF与semaglutide相比，能帮助小鼠减少体重增加并稳定体重
** 公司称，该药物还能改善血糖，减轻肝脏重量，这有助于治疗脂肪肝--一种与肥胖有关的肝病
** 这项为期 12 周的研究是与美国退伍军人管理局合作进行的，研究对象是摄入高脂肪饮食的雌性小鼠。
** 公司表示计划于 2027 年开始人体试验，同时还在开发治疗癌症相关皮肤问题和阿尔茨海默氏症的药物。
** 2025 年股价上涨约 32%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.